Peptimmune to Provide a Progress Report on the Company's Clinical and Non-Clinical Programs.

CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Peptimmune Inc. announced today that Thomas P. Mathers, President and Chief Executive Officer, will speak at the BIO CEO & Investor Conference on Tuesday February 13th at 12pm EST in the Carnegie Suite. The conference will be held at New York's Waldorf-Astoria Hotel. Mr. Mathers' presentation will provide an overview of the progress of the Company.

About Peptimmune:

Peptimmune, Inc. is a privately held clinical stage biotechnology company developing a pipeline of peptide based therapeutics for the treatment of chronic inflammatory diseases. The company is developing second generation therapeutics that are expected to result in safer and more effective therapies for multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis and obesity. Founded by a team of world class scientists and led by an experienced management team, Peptimmune's mission is to reduce the burden these diseases place on the individuals, their families and the healthcare system. For information, access our website at http://www.peptimmune.com/.